LSLaura F. Sandoval

Laura F. Sandoval

*This is an algorithmically generated author record based on publicly available information.

Laura F. Sandoval has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Home ultraviolet light therapy for psoriasis: Why patients choose other options

    by Emily H. Dothard, Laura F. Sandoval, Brad A. Yentzer, Steven R. Feldman

    Background: Psoriasis is a common inflammatory skin condition for which office-based and home phototherapy are safe and effective treatments. However, patients who are prescribed home phototherapy devices often choose other treatment options.Objective: To determine the reasons why patients do not purchase a home phototherapy device after it has been recommended and prescribed by their physician.Methods: Patients who were written a prescription for a home phototherapy device but did not fill the prescription were identified and contacted by the National Biological Corporation to participate in a telephone survey consisting of 4 questions regarding why they did not pursue a prescribed home ultraviolet device and how they were currently treating their psoriasis.Results: The most common reason for not obtaining the prescribed home phototherapy device was using a biologic agent (31%). The second and third most frequently reported reasons were “cost share too high” and “insurance will not cover” (18% and 17%, respectively), together accounting for 35%.Limitations: The reason why patients were prescribed biologics while having an unfilled home phototherapy device prescription was not obtained.Conclusions: Out of pocket cost is a significant barrier to home phototherapy, even to patients who are well insured.


  • Systemic Therapies for Psoriasis: An Evidence-Based Update

    by Laura F. Sandoval, Allison Pierce, Steven R. Feldman


  • Current and future evidence-based acne treatment: a review

    by Laura F Sandoval, Jennifer K Hartel, Steven R Feldman

    (2014). Current and future evidence-based acne treatment: a review. Expert Opinion on Pharmacotherapy: Vol. 15, No. 2, pp. 173-192.


  • Treatment of Preadolescent Acne in the United States: An Analysis of Nationally Representative Data

    by Scott A. Davis, Laura F. Sandoval, Cheryl J. Gustafson, Steven R. Feldman, Kelly M. Cordoro

    The prevalence of acne in younger children is increasing. Of the acne treatments that the U.S. Food and Drug Administration (FDA) has approved for ages 12 years and older, it is unclear which medications are being prescribed off‐label for this younger patient population. The purpose of this study is to compare the therapies being prescribed to preadolescent patients with acne (defined in this study as ages 7 to 11 years) with those being prescribed to adolescent patients (ages 12 to 18 years) and to determine whether prescribing patterns differ between dermatologists and pediatricians. Leading therapies for the treatment of children with a diagnosis of acne were collected from the National Ambulatory Medical Care Survey (NAMCS) from 1993 to 2009. Data were stratified according to age group and physician specialty. Physicians prescribed a wide variety of FDA‐approved and off‐label medications to preadolescent patients with acne. The leading medications were topical treatments, including adapalene (14.4%), benzoyl peroxide (12.8%), and tretinoin (12.5%). Treatment of this age group differed substantially between specialties, with dermatologists frequently prescribing topical retinoids and primary care physicians preferring antibiotics, particularly oral antibiotics. Limitations included a lack of data on acne severity and morphology through NAMCS, as well as the absence of longitudinal data. With the limited number of FDA‐approved treatment options, off‐label prescribing for acne in preadolescent patients is common. Furthermore, this study identified a potential knowledge gap between pediatricians based on their prescribing patterns in this patient population.


  • Open Access

    Adherence to a five day treatment course of topical fluocinonide 0.1% cream in atopic dermatitis

    by Emily Hix, Cheryl J Gustafson, Jenna L O'NEill, Karen Huang, Laura F Sandoval, Jessica Harrison, Adele Clark, Stephen R Feldman

    Background: Adherence in the treatment of chronic inflammatory skin diseases such as atopic dermatitis is poor. Methods to improve adherence have proven difficult.Purpose: To determine whether a short course of treatment with a high-potency corticosteroid will improve adherence compared to longer treatment studies and if improvement in disease and itch continues after treatment.Methods: 10 patients with mild to moderate atopic dermatitis were instructed to apply fluocinonide 0.1% cream twice daily for 5 days. Adherence was self-reported and electronically monitored. Treatment outcomes were assessed in terms of Visual Analog Scale of Itch (VAS), Eczema Area and Severity Index (EASI), and Investigator Global Assessment (IGA) scores.Results: The median adherence rate was 40% (range of 0-100). The median percent change in VAS from baseline measures on days 7 and 14 were 90% (range -13, 100, p=0.02) and 52% (range 0, 100, p=0.004). On days 7 and 14, 20% and 70% patients achieved an EASI-75 and 40% and 60% an IGA of 0 or 1.Limitations: Small sample size limited subgroup analyses.Conclusions: Adherence rates with short-term treatment were similar to previously reported rates in longer term treatment studies. However, even non-adherent patients had significant improvement in itch and disease severity.